



# UNITED STATES PATENT AND TRADEMARK OFFICE

*ck*  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/032,717	10/23/2001	Andre R. Abad	35718/237005 (5718-118)	5409

826 7590 05/18/2006

ALSTON & BIRD LLP  
BANK OF AMERICA PLAZA  
101 SOUTH TRYON STREET, SUITE 4000  
CHARLOTTE, NC 28280-4000

EXAMINER

KUBELIK, ANNE R

ART UNIT PAPER NUMBER

1638

DATE MAILED: 05/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/032,717

Applicant(s)

ABAD ET AL.

Examiner

Anne R. Kubelik

Art Unit

1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 23 February 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-3, 9-12, 17-19, 38-40, 43-46, 49-52 and 55-64 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3, 9-12, 17-19, 38, 43, 46, 49, 52 and 55-64 is/are rejected.
- 7) ☒ Claim(s) 39, 40, 44, 45, 50 and 51 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)):

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: search results

### **DETAILED ACTION**

1. Prosecution in this application has been reopened in light of the modified rejections below.
2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

#### ***Claim Rejections - 35 USC § 112***

3. Claims 1-3, 9-12, 17-19, 38, 43, 46, 49, 52 and 55-64 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for nucleic acids encoding SEQ ID NO:2 and 10, expression cassettes comprising the nucleic acids, plants and seeds comprising a construct comprising the nucleic acid, and a method of using it to impact a plant pest, does not reasonably provide enablement for any nucleic acid that has 90% identity to SEQ ID NO:1, expression cassettes comprising the nucleic acid, plants and seeds comprising a construct comprising the nucleic acid and a method of using it to impact a plant pest. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. The rejection is modified from the rejection set forth in the Office action mailed 6 May 2005. Applicant's arguments filed 23 February 2006 in a Reply Brief have been fully considered but they are not persuasive.

The claims are broadly drawn to any nucleic acid that has 90%, 93%, 94% or 95% identity to SEQ ID NO:1, expression cassettes comprising the nucleic acids, plants and seeds

Art Unit: 1638

comprising constructs comprising the nucleic acids, and a method of using the constructs to impact a plant pest.

The instant specification, however, only provides guidance for methods of assaying the activity of *B. thuringiensis* strain 1218 and lysate against Western corn rootworm and Southern corn rootworm (examples 1 and 2); isolation of crystal protein from the strain and assaying of it for pesticidal activity against western corn rootworm (example 3); identification of two coding regions, *Cry1218-1* and *Cry1218-2* (SEQ ID NO:1 and 3, with SEQ ID NOs:27 and 28 as the genomic clones), isolated by unknown methods, as encoding proteins, SEQ ID NOs:2 and 4, respectively, that have homology to Cry8Ba1 (example 4); production in *E. coli* of truncated proteins, SEQ ID NOs:15 and 17, encoded by SEQ ID NOs:16 and 18, respectively, that are active against southern corn rootworm (example 4); and production of maize-preferred coding sequences of a different truncated version of Cry1218-1 - the nucleic acid is SEQ ID NO:9, which encodes SEQ ID NO:10 (example 5). The specification also teaches making two mutant versions of truncated Cry1218-1 (SEQ ID NO:16), one of which has a truncated N-terminus (comprising amino acids 43-663 of SEQ ID NO:16), and the other in which the 4 amino acid sequence NGSR has been inserted after amino acid 164 - all of these mutant proteins are effective against Colorado potato beetle (example 6) and other mutant proteins (SEQ ID NOs:32, 34, 42 and 46) that have added chymotrypsin cleavage sites - all are more effective against southern and western corn rootworm than Cry1218-1 (example 7). The specification also teaches transformation of maize with SEQ ID NO:9 (examples 8 and 9).

The instant specification fails to provide guidance for nucleic acid that has 90%, 93%, 94% or 95% identity to the full-length of SEQ ID NO:1, expression cassettes comprising the

Art Unit: 1638

nucleic acid, plants and seeds comprising a construct comprising the nucleic acid and a method of using it to impact a plant pest.

The instant specification fails to provide guidance for which amino acids of SEQ ID NO:2 can be altered and to which other amino acids, and which amino acids must not be changed, to maintain Cry8 activity of the encoded protein. The specification also fails to provide guidance for which amino acids can be deleted and which regions of the protein can tolerate insertions and still produce a functional enzyme.

The specification on pg 28, lines 5-16, suggests making these nucleic acids by making conservative substitutions in the encoded protein. However, making “conservative” substitutions (*e.g.*, substituting one polar amino acid for another, or one acidic one for another) does not produce predictable results. Lazar et al (1988, Mol. Cell. Biol. 8:1247-1252) showed that the “conservative” substitution of glutamic acid for aspartic acid at position 47 reduced biological function of transforming growth factor alpha while “nonconservative” substitutions with alanine or asparagine had no effect (abstract). Similarly, Hill et al (1998, Biochem. Biophys. Res. Comm. 244:573-577) teach that when three histidines that are maintained in ADP-glucose pyrophosphorylase across several species are substituted with the “nonconservative” amino acid glutamine, there is little effect on enzyme activity, while the substitution of one of those histidines with the “conservative” amino acid arginine drastically reduced enzyme activity (see Table 1). The nucleic acids encoding all these mutated proteins, however, would have much greater than 90% identity to the nucleic acids encoding the original protein.

Making amino acid substitutions in *cry* proteins is unpredictable. Each *cry* protein only has activity against one or few insect species (de Maagd et al, 1999, Appl. Environ. Microbiol.

Art Unit: 1638

65:4369-4374, see pg 4369, column 1, paragraph 1). Even a single amino acid substitution in a *cry* protein may alter its insecticidal specificity, and toxicity must be determined empirically (Tounsi et al, 2003, J. Appl. Microbiol. 95:23-28; see pg 27, column 2, paragraph 2). For example, a conservative substitution of a lysine for an arginine in a cry11A protein eliminated toxicity to *Aedes aegyptii* but not other pests to which the wild-type protein has toxicity (Angsuthanasombat et al, 2001, J. Biochem. Mol. Biol. 34:402-407, paragraph spanning the columns on pg 405).

The specification, on pg 65, lines 12-14, indicates that the instant SEQ ID NO:1 has homology to GenBank U04365, which is identical to SEQ ID NO:3 of Michaels et al (1996, US Patent 5,554,534). This nucleotide sequence has 85.1% identity to SEQ ID NO:1. The specification, on pg 29, suggests using GenBank U04365 (SEQ ID NO:3 of Michaels et al ) as the other nucleic acid in shuffling to create the claimed nucleic acids; however, it encodes a protein with 79.8% identity to the instant SEQ ID NO:2 (see sequence search report). Thus, this sequence cannot be used as guidance for nucleic acids with 90% identity to SEQ ID NO:1 and that encode proteins with 70% identity to SEQ ID NO:2, as encompassed by the full scope of the claims.

Furthermore, SEQ ID NO:3 of Michaels et al is pesticidal for *Cyclocephala borealis* (northern masked chafer) and *Popillia japonica* (Japanese beetle)(column 14, line 46, to column 15, line 2), whereas the instant SEQ ID NO:1 is pesticidal to *Diabrotica longicornis howardi* (southern corn rootworm). Given the teachings of Tounsi et al, de Maagd et al, and Angsuthanasombat et al, one of skill in the art could not even predict for which pests the protein encoded by nucleic acids that have 90% identity to SEQ ID NO:1 would be toxic, and the

Art Unit: 1638

specification does not teach which amino acid substitutions must can be made to retain southern corn rootworm pesticidal activity.

Given the claim breath, unpredictability, and lack of guidance as discussed above, undue experimentation would have been required by one skilled in the art to develop and evaluate nucleic acids with 90% identity to SEQ ID NO:1 or that hybridizes to SEQ ID NO:1. Making all possible single amino acid substitutions, in an 3621 nucleotide long nucleic acid like that of SEQ ID NO:1 would require making and analyzing  $19^{3621}$  nucleic acids; these nucleic acids would have about 99.99% identity to SEQ ID NO:1. Because nucleic acids that have 90% identity to SEQ ID NO:1 would have up to 362 nucleotide substitutions, many more than  $19^{3621}$  nucleic acids would need to be made and analyzed.

Furthermore, because nucleic acids that have 90% identity to SEQ ID NO:1 would have up to 362 nucleotide substitutions, they could encode proteins with up to 362 amino acid substitutions; these proteins would have 70% identity to the 1206 amino acid long SEQ ID NO:2. The specification provides no guidance for which 362 amino acids to substitute. Thus, undue trial and error experimentation would be required to make the claimed nucleic acids.

Similarly, nucleic acids that have 93% identity to SEQ ID NO:1 would have up to 253 nucleotide substitutions, nucleic acids that have 94% identity to SEQ ID NO:1 would have up to 217 nucleotide substitutions and nucleic acids that have 90% identity to SEQ ID NO:1 would have up to 181 nucleotide substitutions, producing proteins with 79%, 82% and 85% identity, respectively, to the 1206 amino acid long SEQ ID NO:2.

Guo et al (2004, Proc. Natl. Acad. Sci. USA 101: 9205-9210) teach that while proteins are fairly tolerant to mutations resulting in single amino acid changes, increasing the number of

Art Unit: 1638

substitutions additively increases the probability that the protein will be inactivated (pg 9209, right column, paragraph 2). Thus, making and analyzing proteins with up to 363 amino acid substitutions that also have pesticidal activity would require undue experimentation.

As the specification does not describe the transformation of any plant with nucleic acids with 90% identity to SEQ ID NO:1 within the full scope of the claims, undue trial and error experimentation would be required to screen through the myriad of nucleic acids encompassed by the claims and plants transformed therewith, to identify those that could control plant pests, if such plants are even obtainable.

Given the claim breadth, unpredictability in the art, undue experimentation, and lack of guidance in the specification as discussed above, the instant invention is not enabled throughout the full scope of the claims.

Applicant urges that the specification provides 14 variants of SEQ ID NO:1; these have between 38% and 92% identity across the full-length of SEQ ID NO:1 (Reply Brief pg 3-4 and Table 1).

This is not found persuasive.

First, Applicant has numerous errors in Table 1. The amino acids listed as deleted are not the deleted amino acids; they are the ones still present in the protein. Examiner has not recalculated nucleotide or amino acid identity for the sequences, but it is noted that in Applicant's previous responses, SEQ ID NO:19 was indicated as having different percent global identity to SEQ ID NO:1.



Art Unit: 1638

Second, one of skill in the art would not consider a truncated protein as having 56% identity to the entire length of SEQ ID NO:2, but would only look at it as a truncated protein. One of skill in the art would only look at local match similarity. That the specification provides guidance in making truncations at amino acid 663, 699 and 667, eliminating the C-terminus, and truncations off a portion of the N-terminus (in which the first 47 amino acids are eliminated) is not disputed. However, this is not the genus of claimed nucleic acids.

Third, the specification does not consider deletions the same thing as substitutions. See pg 19, lines 3-10 and pg 28, lines 5-31, in which deletions and substitutions are discussed in the alternative.

Fourth, these sequences (except SEQ ID NO:3/4) teach a maximum of 4 amino acid substitutions. One of skill in the art would not consider these sequences as teaching which 181, 217, 253 or 362 amino acids to substitute in SEQ ID NO:2.

Fifth, SEQ ID NO:3 differs from SEQ ID NO:1 in primarily in a 400 nucleotide long region (see search results). Because the vast majority of substitutions are localized to such a small area, the protein it encodes, SEQ ID NO:4 has 89% identity to SEQ ID NO:2. Thus, SEQ ID NO:3 cannot provide guidance for making nucleic acids with 90% identity to SEQ ID NO:1 and encoding a protein with 362 amino acid substitutions relative to SEQ ID NO:2.

In summary, making fragments and a single 4 amino acid substitution are not the same thing as making 362 amino acid substitutions. The specification fails to enable nucleic acids within the full scope of the claims.

Applicant urges that SEQ ID NO:19 comprises 1860 nucleotides of SEQ ID NO:1 and retains identity, pointing to the likelihood that alteration of one or more of the 1761 additional

Art Unit: 1638

nucleotides in SEQ ID NO:1 could be altered without disrupting function; furthermore, SEQ ID NO:9 encodes the same protein as SEQ ID NO:19 but has maize optimized codons, and it shares 38% global identity to SEQ ID NO:1 and 68% local identity (Reply Brief pg 4).

This is not found persuasive. SEQ ID NOs:19 and 9 encode proteins with 100% identity to the first half of SEQ ID NO:2. One of skill in the art would not consider a truncated protein as providing guidance for making amino acid substitutions in SEQ ID NO:2. Substitutions in the latter half of the protein affect the folding of the entire protein, and cannot be made willy-nilly just because a protein can be truncated.

Applicant urges that the examiner overlooks the guidance in the specification as to which 362, 253 or 217 nucleotides of SEQ ID NO:1 could be altered; guidance is provided on pg 23-24, 29 and examples 1, 6 and 7 (Reply Brief pg 8).

This is not found persuasive. Pg 23 provided general guidance for methods of making mutations in nucleic acids. It does not provide guidance for which 362 amino acid substitutions to make in SEQ ID NO:2.

Pg 24 teaches that cry proteins have conserved blocks. However, Hill et al teach that conserved blocks cannot be relied on in making amino acid substitutions (see Table 1).

The specification, on pg 29, suggests using GenBank U04365 as the other nucleic acid in shuffling to create the claimed nucleic acids; however, it encodes a protein with 79.8% identity to the instant SEQ ID NO:2. Thus, this sequence cannot be used as guidance for nucleic acids with 90% identity to SEQ ID NO:1 and that encode proteins with 70% identity to SEQ ID NO:2, as encompassed by the full scope of the claims.

Furthermore, SEQ ID NO:3 of Michaels et al is pesticidal for scarab pests (see claim 1),

Art Unit: 1638

whereas the instant SEQ ID NO:1 is pesticidal to southern corn rootworm. Given the teachings of Tounsi et al, de Maagd et al, and Angsuthanasombat et al, one of skill in the art could not even predict for which pests the protein encoded by nucleic acids that have 90% identity to SEQ ID NO:1 would be toxic, and the specification does not teach which amino acid substitutions made to retain proper pesticidal activity.

Examples 1, 6 and 7 teach making the truncations and the 4 amino acid substitutions presented in Table 1 of the Reply Brief. Why these examples do not teach nucleic acids within the full scope of the claims is discussed above.

Making amino acid substitutions in *cry* proteins is unpredictable. Even a single amino acid substitution in a *cry* protein may alter its insecticidal specificity, and toxicity must be determined empirically (Tounsi et al, 2003, J. Appl. Microbiol. 95:23-28; see pg 27, column 2, paragraph 2). Thus the specification must teach how to make nucleic acids within the full scope of the claims. It does not.

The specification on pg 3, lines 4-8, even acknowledges the unpredictability in making amino acid substitutions in Cry proteins:

Although numerous investigators have attempted to make mutant endotoxin proteins with improved insecticidal activity, few have succeeded. In fact, the majority of genetically engineered *B. thuringiensis* toxins that have been reported in the literature report endotoxin activity that is no better than that of the wild-type protein, and in many cases, the activity is decreased or destroyed altogether.

Applicant urges that the examiner overlooks the guidance in Li et al, as citing on pg 25 of the specification, and Applicant's data on the truncated proteins (Reply Brief pg 8-10).

This is not found persuasive. The guidance in Li et al was not overlooked. However, Li et al only provided guidance for making truncations and insertion of chymotrypsin cleavage sites; Li et al do not provide guidance for making 181, 217, 253 or 362 amino acid substitutions

Art Unit: 1638

in a 1206 amino acid protein. The instant inventors did not use Li et al to make 181, 217, 253 or 362 amino acid substitutions in a 1206 amino acid protein to create a Coleopteran pesticidal protein. Furthermore, truncated proteins are not the same as substituted proteins, as discussed above.

Applicant urges that some experimentation would be necessary to make and use other embodiments of the invention, but it would not be undue, given the guidance in the specification (Reply Brief pg 10-11).

This is not found persuasive. Such experimentation would be undue because of the lack of guidance in the specification and the unpredictability in making amino acid substitutions in *cry* proteins. See the specification on pg 3, lines 4-8, as well as Tounsi et al, de Maagd et al, and Angsuthanasombat et al, as discussed above.

Applicant urges that Lazar is drawn to a mammalian protein unrelated to the instant Cry protein, and the amino acids modified in that paper were known to be conserved, unsurprisingly leading to a loss of function (Reply Brief pg 11-12).

This is not found persuasive. Lazar et al was testing the commonly accepted notion that making conservative substitutions would not affect activity and that nonconservative substitutions would affect activity, even inactivate the protein. Lazar et al were surprised to find that this was not the case - conservative substitutions inactivated the protein and nonconservative substitutions has no effect on activity. This is relevant to the instant case because the specification, on pg 28, lines 5-16, teaches that amino acid substitutions should be conservative. Lazar et al teaches that functional substitutions must be determined empirically. The specification does teach which substitutions to make within the full scope of the claims.

Applicant urges that Hill et al is drawn to an enzyme unrelated to the instant Cry protein, and the modified residues were highly conserved, unsurprisingly leading to a loss of function (Reply Brief pg 12-13).

This is not found persuasive. Hill et al was testing the commonly accepted notion that amino acids conserved across proteins from a wide range of species can only tolerate conservative substitutions if they can tolerate any at all. Hill et al were surprised to find that this was not the case - nonconservative substitutions had no effect on activity and conservative substitutions inactivated the protein. This is relevant to the instant case because the specification, on pg 28, lines 5-16, teaches that amino acid substitutions should be conservative and on pg 24-25 teaches that other cry proteins can be used as comparisons when making the claimed nucleic acids. Hill et al teaches that functional substitutions must be determined empirically. The specification does teach which substitutions to make within the full scope of the claims.

Applicant urges that Lazar et al and Hill et al demonstrate that one of skill in the art could make substitutions in proteins and test for activity (Reply Brief pg 13).

This is not found persuasive. Lazar et al and Hill et al made single amino acid substitutions. The claims encompass nucleic acids that having 90% identity to SEQ ID NO:1 and encoding functional Cry proteins with 362 amino acid substitutions. Guo et al teaches that increasing the number of substitutions above single amino acid changes additively increases the probability that the protein will be inactivated (pg 9209, right column, paragraph 2). Thus, without further guidance, one of skill in the art could not make this many substitutions and still produce functional proteins.

Art Unit: 1638

Applicant urges that there is guidance in the specification for making modifications (Reply Brief pg 13).

This is not found persuasive because the specification fails to provide guidance for making nucleic acids that having 90% identity to SEQ ID NO:1 and encoding functional Cry proteins with 362 amino acid substitutions, as encompassed by the full scope of the claims.

4. Claims 1-3, 9-12, 17-19, 38, 43, 46, 49, 52 and 55-64 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The rejection is repeated for the reasons of record as set forth in the Office action mailed 6 May 2005. Applicant's arguments filed 23 February 2006 in a Reply Brief have been fully considered but they are not persuasive.

A full review of the specification indicates that nucleic acids that have 90%, 93%, 94% or 95% identity to SEQ ID NO:1 and that encode Coleopteran-pesticides are essential to the operation of the claimed invention.

The level of skill and knowledge in the art at the time of filing was such that while large number of Coleopteran-pesticides were known, nucleic acids that have 90%, 93%, 94% or 95% identity to SEQ ID NO:1 and that encode such Coleopteran-pesticides were not.

The claim is directed to a genus of nucleic acids that have 90%, 93%, 94% or 95% identity to SEQ ID NO:1. Nucleic acids that have 90%, 93%, 94% or 95% identity to SEQ ID NO:1 would have up to 362 nucleotide substitutions, they could encode proteins with up to 362,

Art Unit: 1638

253, 217 or 181 amino acid substitutions relative to the to the 1206 amino acid long SEQ ID NO:2.

The structural features that distinguish Coleopteran-pesticide-encoding nucleic acids that have 90%, 93%, 94% or 95% identity to SEQ ID NO:1 from other that have 90%, 93%, 94% or 95% identity to SEQ ID NO:1 are not described in the specification. The specification recites no structure required for Coleopteran-pesticide activity. The necessary and sufficient structural elements of a protein with Coleopteran-pesticide activity are not described.

The only species described in the specification is SEQ ID NO:1, which encodes SEQ ID NO:2, a truncated version of SEQ ID NO:1, and a few nucleic acids with a few nucleotide substitutions relative to SEQ ID NO:1.

One of skill in the art would not recognize that Applicant was in possession of the necessary common attributes or features of the genus in view of the disclosed species. Since the disclosure fails to describe the common attributes that identify members of the genus, and because the genus is highly variant, SEQ ID NO:1 alone is insufficient to describe the claimed genus.

Hence, Applicant has not, in fact, described nucleic acids with 90%, 93%, 94% or 95% identity to SEQ ID NO:1 and that encode a protein pesticidal for at least one pest belonging to the order Coleoptera within the full scope of the claims, and the specification fails to provide an adequate written description of the claimed invention.

Therefore, given the lack of written description in the specification with regard to the structural and physical characteristics of the claimed compositions, it is not clear that Applicant was in possession of the genus claimed at the time this application was filed.

Art Unit: 1638

Applicant urges that the specification provides numerous nucleic acids that fall within the scope of the claims as well as much guidance for making alterations (Reply Brief pg 15).

This is not found persuasive because the structure of nucleic acids that have 90%, 93%, 94% or 95% identity to SEQ ID NO:1 and up to 362, 253, 217 or 181 amino acid substitutions, respectively, relative to the to the 1206 amino acid long SEQ ID NO:2 as encompassed by the full scope of the claims are not described.

Applicant urges that in *Lilly* the patent did not identify the sequence of any embodiment, while here a representative sequence is provided (Reply Brief pg 15).

This is not found persuasive. In *Lilly* the claims were drawn to the genus of vertebrate and mammalian cDNAs and the rat cDNA was described. Lilly stated at pg 1406:

... A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus.

In the instant case, only a portion of the structural features have been described - the percent identity to SEQ ID NO:1. But because this includes nucleic acids in which the protein sequence has a very large number of amino acid substitutions, those amino acid substitutions that do not alter the function of the protein must be described. They are not. A representative number of nucleic acids that have 90%, 93%, 94% or 95% identity to SEQ ID NO:1 and up to 362, 253, 217 or 181 amino acid substitutions, respectively, relative to the to the 1206 amino acid long SEQ ID NO:2 are not described.

5. Claims 39-40, 44-45 and 50-51 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.



Art Unit: 1638

**Conclusion**

6. No claim is allowed.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.


The central fax number for official correspondence is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.


Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Anne Kubelik, Ph.D.  
April 28, 2006



ANNE KUBELIK, PH.D.  
PRIMARY EXAMINER



ANNE MARIE GRUNBERG  
SUPERVISORY PATENT EXAMINER

```
Db 3191 ATTGGTCAATCAAGACCGGATGTAAAGAAATGTACCGGATGTTCTGCTCCAGATGTA 3250
Qy 2521 TCTCTGTTAACTCGGATGTAGTATCAATGCAATGACGAGCAAAAGATATGTCAATAGC 2580
Db 3251 TCTCTGTTAACTCGGATGTAGTATCAATGCAATGACGAGCAAAAGATATGTCAATAGC 3310
Qy 2581 CGTTTAAAGTATGAAACCGTCTCGTGAAGCGCATAGTCTCTATTCTCTATTGATACA 2640
Db 3311 CGTTTAAAGTATGAAACCGTCTCGTGAAGCGCATAGTCTCTATTCTCTATTGATACA 3370
Qy 2641 CGTGAATTCATTAATGAAATGCGGATATGCGGATATGCGTGGATTTAAAGTACGACCCA 2700
Db 3371 GGTGAATTCATTAATGAAATGCGGATATGCGGATATGCGTGGATTTAAAGTACGACCCA 3430
Qy 2701 GAGGGATATGCAACACTCGGAACCTAGGAATGTGCGAAGGAGCACTTTATCAGAGAC 2760
Db 3431 GAGGGATATGCAACACTCGGAACCTAGGAATGTGCGAAGGAGCACTTTATCAGAGAC 3490
Qy 2761 GCATTAGAACCTTGCAGAGGAGCAACAGTGTGAGATTCAAATGCAAGAGAGCT 2820
Db 3491 GCATTAGAACCTTGCAGAGGAGCAACAGTGTGAGATTCAAATGCAAGAGAGCT 3550
Qy 2821 GAAGAAACAGATAGAGGATATGCGCATCGAAACAGCGGTAGATGCTTTATATGCCGAT 2880
Db 3551 GAAGAAACAGATAGAGGATATGCGCATCGAAACAGCGGTAGATGCTTTATATGCCGAT 3610
Qy 2881 TATCAGGATCAGCAACTGATCTGATGTAGAGATTTACAGATCTTACTGCGGCCCAAGAT 2940
Db 3611 TATCAGGATCAGCAACTGATCTGATGTAGAGATTTACAGATCTTACTGCGGCCCAAGAT 3670
Qy 2941 CTGATACAGTCCATCTTCACTGATATAACAGAAATGTTCCAGAAATACCAAGGATCAAC 3000
Db 3671 CTGATACAGTCCATCTTCACTGATATAACAGAAATGTTCCAGAAATACCAAGGATCAAC 3060
Qy 3001 TATACGAAGTTTACAGATTTAAACAGATCGACTTCAACAGCGGTGAGTTGTATGATCAG 3060
Db 3731 TATACGAAGTTTACAGATTTAAACAGATCGACTTCAACAGCGGTGAGTTGTATGATCAG 3060
Qy 3061 CGAAATGCAATACCAATGATGTTTCAAAATGGGTTAGTAATGGAATGCAAGCGCT 3120
Db 3791 CGAAATGCAATACCAATGATGTTTCAAAATGGGTTAGTAATGGAATGCAAGCGCT 3850
Qy 3121 GCGGTAGAGTACACAAATCAATCATCATCTGCTCTGTTGATTCCAAACTGCGGATGAG 3180
Db 3851 GCGGTAGAGTACACAAATCAATCATCATCTGCTCTGTTGATTCCAAACTGCGGATGAG 3180
Qy 3181 CAAAGTTTCCGCAAGTTTACAGTTCAACCGAATCAAGATATGTTACGAGTTACTGCG 3240
Db 3911 CAAAGTTTCCGCAAGTTTACAGTTCAACCGAATCAAGATATGTTACGAGTTACTGCG 3240
Qy 3241 AGAAAGAGAGGGGTAGGAAATGGATATGTAAGTATCCGTGATGGTGGAATCAAAACAGAA 3300
Db 3971 AGAAAGAGAGGGGTAGGAAATGGATATGTAAGTATCCGTGATGGTGGAATCAAAACAGAA 4030
Qy 3301 ACGCTTACTTTTACTGCAAGCGATATGATATCAAAATGGATATGTAAGTATGTAAGTATG 3360
Db 4031 ACGCTTACTTTTACTGCAAGCGATATGATATCAAAATGGATATGTAAGTATGTAAGTATG 4090
Qy 3361 AATACAAAATGGAATATGATATGATATGATATGATATGATATGATATGATATGATATG 3420
Db 4091 AATACAAAATGGAATATGATATGATATGATATGATATGATATGATATGATATGATATG 4150
Qy 3421 TATAACGCAAAATATGATATGATATGATATGATATGATATGATATGATATGATATGATAT 3480
Db 4151 TATAACGCAAAATATGATATGATATGATATGATATGATATGATATGATATGATATGATAT 4210
Qy 3481 AGTGTGTACAAATCAAAACCGGCTATATCAAAAAACAGTACATTCATCCCTATAC 3540
Db 4211 AGTGTGTACAAATCAAAACCGGCTATATCAAAAAACAGTACATTCATCCCTATAC 4270
Qy 3541 GATCAAAATGGAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 3600
```

```
Db 4271 GATCAAAATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGA 4330
Qy 3601 TTGATTGTAGACGTAGAGTAA 3621
Db 4331 TTGATTGTAGACGTAGAGTAA 4351

RESULT 3
US-10-032-717-3
; Sequence 3, Application US/10032717
; Patent No. US20020151709A1
; GENERAL INFORMATION:
; APPLICANT: Andre R. Abad
; APPLICANT: Nicholas B. Duck
; APPLICANT: Xiang Peng
; APPLICANT: Ronald D. Flannagan
; APPLICANT: Theodore W. Kahn
; APPLICANT: Lynn E. Sims
; TITLE OF INVENTION: Genes Encoding No. US20020151709A1el Proteins With
; FILE REFERENCE: 35718/237005
; CURRENT APPLICATION NUMBER: US/10/032.717
; CURRENT FILING DATE: 2001-10-23
; PRIOR APPLICATION NUMBER: 60/242,838
; PRIOR FILING DATE: 2000-10-24
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 3633
; TYPE: DNA
; ORGANISM: Bacillus thuringiensis
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)...(3633)
; NAME/KEY: misc. feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: Cry121B-2
US-10-032-717-3
```

```
Query Match 87.0%; Score 3151.8; DB 12; Length 3633;
Best Local Similarity 92.1%; Pred. No. 0;
Matches 3353; Conservative 0; Mismatches 262; Indels 24; Gaps 2;
```

```
Qy 1 ATGAGTCCAAATTAATCAAAATCAATTAATCAAAATTAATCAAAATTAATCAAAATTAAT 60
Db 1 ATGAGTCCAAATTAATCAAAATCAATTAATCAAAATTAATCAAAATTAATCAAAATTAAT 60
Qy 61 TCCAAATGATTTAAACAGATACCCCTTTTCGGAATGAGCCCAACAAATGCGCTACAAAATATG 120
Db 61 TCCAAATGATTTAAACAGATACCCCTTTTCGGAATGAGCCCAACAAATGCGCTACAAAATATG 120
Qy 121 GATTATTAAGATTTATTTAATAATGCTCGCGGAATGCTAGTGAATACCCCTGTTCACT 180
Db 121 GATTATTAAGATTTATTTAATAATGCTCGCGGAATGCTAGTGAATACCCCTGTTCACT 180
Qy 181 GAAGTACTTTGTTAGCGGACAGATGCACTTAAGCCCGCAATTTGATATAGTAGGTAATA 240
Db 181 GAAGTACTTTGTTAGCGGACAGATGCACTTAAGCCCGCAATTTGATATAGTAGGTAATA 240
Qy 241 CTATCAGGTTTATGAGGCTCCCTTTGTTGCGGCGCATAGTACTTTTATCTCACTTAT 300
Db 241 CTATCAGGTTTATGAGGCTCCCTTTGTTGCGGCGCATAGTACTTTTATCTCACTTAT 300
Qy 301 GATATTTCTGTGGCTTCAGGGGAAAGAGTCAATGCGGAATTTTATGGAACAAGTAGAA 360
Db 301 GATATTTCTGTGGCTTCAGGGGAAAGAGTCAATGCGGAATTTTATGGAACAAGTAGAA 360
Qy 361 GAATCTCAATTAATCAAAAAATAGCAGATATCAAGGAATAAAGCGCTTTCGGAATTAGAA 420
Db 361 GAATCTCAATTAATCAAAAAATAGCAGATATCAAGGAATAAAGCGCTTTCGGAATTAGAA 420
Qy 421 GGATTAGGTAATAATTAACCAATTTATCTTAAGTGGCTGGAAGATGGAAGAAATCCA 480
```

Db 421 GGATTAGGTAATAATACCAATTATATCTAACTGCGCTTGAAGAAATGGAAAGAAATCCA 480  
Qy 481 AATGGTTCAAGAGCCTTACGAGATGTCGGAATTCGAATTTGAAATCCGAGTAGTTATTT 540  
Db 481 AATGGTTCAAGAGCCTTACGAGATGTCGGAATTCGAATTTGAAATCCGAGTAGTTATTT 540  
Qy 541 ACGCAATATATGCCATCTTTAGAGTGAACAATTTTGAAGTACCAATTCCTTACTGTATAT 600  
Db 541 ACGCAATATATGCCATCTTTAGAGTGAACAATTTTGAAGTACCAATTCCTTACTGTATAT 600  
Qy 601 GCAATGGCAGCAACCTTCAATTTACTGTATTAAGAGCGCTCAATTTTGGAGAGAA 660  
Db 601 ACACAGGCGACCACTTCAATTTACTGTATTAAGAGCGCTCAATTTTGGAGAGAA 660  
Qy 661 TGGGATGGTCAACACTACTATTAATTAATCTATATGATCGTCAATTTGAAATCTACTGCA 720  
Db 661 TGGGATGGTCAACACTACTATTAATTAATCTATATGATCGTCAATTTGAAATCTACTGCA 720  
Qy 721 GAATATTTCTGATCACTGTGTAAGTGGTATGAACCTGGTTTGAAGCAAAATTAAGAGCGACG 780  
Db 721 GAATATTTCTGATCACTGTGTAAGTGGTATGAACCTGGTTTGAAGCAAAATTAAGAGCGACG 780  
Qy 781 AGCGCTTAACATGSGTTGACTATAACCAATTCGCTAGAGAAATGACATCGCGGTTTTA 840  
Db 781 AGCGCTTAACATGSGTTGACTATAACCAATTCGCTAGAGAAATGACATCGCGGTTTTA 840  
Qy 841 GATGTGTGCTATTAATCCCAATTTATGACACACGCGTACCCAAATGGAACGAAAGCA 900  
Db 841 GATGTGTGCTATTAATCCCAATTTATGACACACGCGTACCCAAATGGAACGAAAGCA 900  
Qy 901 CAATTAACAGGAGTATATACAGATCACTGCGGCGGTAAACGTGCTTCAATTTGTT 960  
Db 901 CAATTAACAGGAGTATATACAGATCACTGCGGCGGTAAACGTGCTTCAATTTGTT 960  
Qy 961 TCTGGTATGACAAAGCCTTCTTTCGGAGTGAATGATATCCGTTATTCGACACCC 1020  
Db 961 TCTGGTATGACAAAGCCTTCTTTCGGAGTGAATGATATCCGTTATTCGACACCC 1020  
Qy 1021 CATGTATTGTGATTAATACGGGACTCAAGTGTATACCAATCAAGAGCAATTTCTTCC 1080  
Db 1021 CATGTATTGTGATTAATACGGGACTCAAGTGTATACCAATCAAGAGCAATTTCTTCC 1080  
Qy 1081 GCTCGCTATATAGACATTTGGGCTGGTTCATCAATAGCTTACCATCGTCTAGTAGGGGT 1140  
Db 1081 GCTCGCTATATAGACATTTGGGCTGGTTCATCAATAGCTTACCATCGTCTAGTAGGTAT 1140  
Qy 1141 AGTAATCTTCAACAAATGTATGGAATCAATCAAAATCTACAGCACTAGTACCTTTGAT 1200  
Db 1141 AATATTATTAACACAGATGTATGGAATCAATCAAAATCTACAGCACTAGTACCTTTGAT 1200  
Qy 1201 TTTACGAATTTATGATATTTACAGACTATCAAGAGTGCAGTACTCCTTGTATTTGTT 1260  
Db 1201 TTTACGAATTTATGATATTTACAGACTATCAAGAGTGCAGTACTCCTTGTATTTGTT 1260  
Qy 1261 TACCTCGTTATATCGTATATATTTTGGAAATGCGAGAGTCCAGTTTTCATGTTAAAC 1320  
Db 1261 TTTCTCGTTATATCGTATATATTTTGGAAATGCGAGAGTCCAGTTTTCATGTTAAAC 1320  
Qy 1321 CAATTTGAATTAATACCAAGAGCGTTAAAGTATTAATCCAGTTTCCAAAGATATATAGCG 1380  
Db 1321 CAATTTGAATTAATACCAAGAGCGTTAAAGTATTAATCCAGTTTCCAAAGATATATAGCG 1380  
Qy 1381 AGTACAGAGATTCGGAATTAAGATTAATCCAGAGTCCAGAGTCCAGATCAACCAATTTATGAG 1440  
Db 1381 GGGACAGAGATTCGGAATTAAGATTAATCCAGAGTCCAGAGTCCAGATCAACCAATTTATGAG 1440  
Qy 1441 TCATATAGCCATAGATTAATGTCATATCAAGATTTTCCCGCAGCGGTAACTACCGGA 1500  
Db 1441 TCATATAGCCATAGATTAATGTCATATCAAGATTTTCCCGCAGCGGTAACTACCGGA 1500  
Qy 1501 TTAGTACCTGTATTTCTTGGACACATCGAGTGCAGATTTTAAACATATATATATCA 1560  
Db 1501 TTAGTACCTGTATTTCTTGGACACATCGAGTGCAGATTTTAAATGAGTTCATATCA 1560

Qy 1561 GATAAATCACTCAAAATTCGCGCGCTTAAATGTTGGGATAATTTTACCGTTTGT ----- 1613  
Db 1561 GATAAATCACTCAAAATTCGCGCGCTTAAATGTTGGGATAATTTTACCGTTTGT ----- 1620  
Qy 1614 -----TCCAGTGTGTAAGAGCAACGAGACATACAGAGGGGGATTTTACAGTAT 1662  
Db 1621 GGGGCAATTAATACCGTTGATCGGGTCTCGGATTTACAGGGGGGGGATTAATAAGATA 1680  
Qy 1663 AATAGAGTACTGTTCTGTAGGAACCTTATTTCTAGCTCGATATGGCTAGCATTAGAA 1722  
Db 1681 AATAGAGTACTGTTCTGTAGGAACCTTATTTCTAGCTCGATATGGCTAGCATTAGAA 1740  
Qy 1723 AAGCAGGGGAAATATCTGTGTAAGACTGAGATGCTACTGATGAGATATTTGTATTCAT 1782  
Db 1741 TATAGTATAGGATTCGTTATGCTTCCGCTAATATCTGAAATTTTATATAATCCCTCT 1800  
Qy 1783 GTAAACGATGCTCAGATTCAGATGCGCAAAACAAATGAACCCAGGTGAGGATCTGACATCT 1842  
Db 1801 GAAGAAACGTTAAATCTCACTCGCTCAAAACAACTATGAAATAGAGCTTAAACATAT 1860  
Qy 1843 AAAACCTTTAAAGTTGCAAGTCTATCACAAATTAATTTTAGCAACAGATAGTTGCGCTA 1902  
Db 1861 AATAAATTAATATGCGACTTTGCGCCCTATTAATTTTACGACAAACCGACCTTTCAAT 1920  
Qy 1903 GCATTTGAAACATTAATTTAGGTGAAGACCTTAATTCACATATCTGCTATGATTTACGTT 1962  
Db 1921 ACTCTAGGGGCTATATTTGAAGCGGAGACTTTCTTGGAAAT-----TGNAGCTTATATA 1974  
Qy 1963 GACCGAATTCGAATTCATCCAGTAGATGAGACATATGAAGCGGAAACAAAGATTTAGAAGCA 2022  
Db 1975 GACCGAATTCGAATTTATCCAGTAGATGAGACATATGAAGCGGAAACAAAGATTTAGAAGCA 2034  
Qy 2023 GCGAAGAAACGAGTGAATGCTTGTTCGAAATACAAAGATGCGCTTACGACCGGCTA 2082  
Db 2035 GCGAAGAAACGAGTGAATGCTTGTTCGAAATACAAAGATGCGCTTACGACCGGCTA 2094  
Qy 2083 ACGGATTAATGAAGTGAATCAAGCGGCAAACTTAGTGAAGATGCTATCGGATGATTTGAT 2142  
Db 2095 ACGGATTAATGAAGTGAATCAAGCGGCAAACTTAGTGAAGATGCTATCGGATGATTTGAT 2154  
Qy 2143 CCNAATGAAACCGATTTGATTTGATGAGAGGCAAACTTAGTGAAGATGCTATCGGATGATTTGAT 2202  
Db 2155 CCNAATGAAACCGATTTGATTTGATGAGAGGCAAACTTAGTGAAGATGCTATCGGATGATTTGAT 2214  
Qy 2203 GGTAAATTTGCTTCAAGATCCAGATTTCCAGAGATTAATGAGGAAATGCTTGAAGGCA 2262  
Db 2215 GGTAAATTTGCTTCAAGATCCAGATTTCCAGAGATTAATGAGGAAATGCTTGAAGGCA 2274  
Qy 2263 AGTACGGGAATTTGAGGTTATAGAGGGGATGCTTTATTTCAAGGGCGTTTATCTACGCTTA 2322  
Db 2275 AGTACGGGAATTTGAGGTTATAGAGGGGATGCTTTATTTCAAGGGCGTTTATCTACGCTTA 2334  
Qy 2323 CCAGTGGGAGAGAAATAGATACGGAACGATATCCAAAGTATCTGTTATCCAAAGTAGAG 2382  
Db 2335 CCAGTGGGAGAGAAATAGATACGGAACGATATCCAAAGTATCTGTTATCCAAAGTAGAG 2394  
Qy 2383 GAAGGTGTTATTAACCAATACAGATATAGATTTGAGAGGGTTTGTGCGAGAGCTGCA 2442  
Db 2395 GAAGGTGTTATTAACCAATACAGATATAGATTTGAGAGGGTTTGTGCGAGAGCTGCA 2454  
Qy 2443 GGAATTTGGAATTTTCAATTTCTGCTCAATCCAAACCGAATTTGTAAGGATTCACCGAT 2502  
Db 2455 GGAATTTGGAATTTTCAATTTCTGCTCAATCCAAACCGAATTTGTAAGGATTCACCGAT 2514  
Qy 2503 GATTTGCTGCGAGATGATCTCTGTTAACTCGGATGAGTATCAATCGATGAGCGAA 2562  
Db 2515 GATTTGCTGCGAGATGATCTCTGTTAACTCGGATGAGTATCAATCGATGAGCGAA 2574  
Qy 2563 CAAGAATGATGGAATAGCGCTTTAGAGTAGAGAAACCGTTCTGCTGGAAGCGCATGAGTTC 2622  
Db 2575 CAAGAATGATGGAATAGCGCTTTAGAGTAGAGAAACCGTTCTGCTGGAAGCGCATGAGTTC 2634

```
QY 2623 TCTATTCCTATTGATACAGTGTGAATTCAGATTAATGAAATGCAAGGAATATGGTTGGA 2682
Db 2635 TCTATTCCTATTGATACAGTGTGAATTCAGATTAATGAAATGCAAGGAATATGGTTGGA 2694
QY 2683 TTTAAGATTACGGAACCCAGAGGATATGCAACTCGGAACTTAGAATTTGGTCDAAAGAG 2742
Db 2695 TTTAAGATTACGGAACCCAGAGGATATGCAACTCGGAACTTAGAATTTGGTCDAAAGAG 2754
QY 2743 GGACCTTTATCAGGAGACCATTTAGAACTCTGCAAGGAGAGACACACATGCGAATTT 2802
Db 2755 GGACCTTTATCAGGAGACCATTTAGAACTCTGCAAGGAGAGACACACATGCGAATTT 2814
QY 2803 CAATATGACAGAGAGACGTGAAGAAACAGATAGAGGTATATGGCATCGAAACAGCGGTA 2862
Db 2815 CAATATGACAGAGAGACGTGAAGAAACAGATAGAGGTATATGGCATCGAAACAGCGGTA 2874
QY 2863 GATCGTTTATATGCCAATATACAGATACAGAACTGAAATCTCGATGTAGAGTTACAGAT 2922
Db 2875 GATCGTTTATATGCCAATATACAGATACAGAACTGAAATCTCGATGTAGAGTTACAGAT 2934
QY 2923 CTCTACTGGGCCCGAGATCTGATACAGTCCATTCCTTACGTATATACGAATTTCCCA 2982
Db 2935 CTCTACTGGGCCCGAGATCTGATACAGTCCATTCCTTACGTATATACGAATTTCCCA 2994
QY 2983 GAAATACACAGGATGAATATACCAAGTTTACAGATTTAAACAGATTCGAATCCCAAGCG 3042
Db 2995 GAAATACACAGGATGAATATACCAAGTTTACAGATTTAAACAGATTCGAATCCCAAGCG 3054
QY 3043 TCGAGTTTGTATGATCAGCGAAATGCGCATACCAATGTGTATTTTCAAAATGGGTTAAGT 3102
Db 3055 TCGAGTTTGTATGATCAGCGAAATGCGCATACCAATGTGTATTTTCAAAATGGGTTAAGT 3114
QY 3103 AATTGGAATGCAAGCGCTGCGGTAGAGGTACAAACAAATCAATCATACATCTGCTTGTG 3162
Db 3115 AATTGGAATGCAAGCGCTGCGGTAGAGGTACAAACAAATCAATCATACATCTGCTTGTG 3174
QY 3163 ATTCCAAATCGGATGAGCAAGTTTGGCAAGTTTACAGTTTCAACCGAATCAAGATAT 3222
Db 3175 ATTCCAAATCGGATGAGCAAGTTTGGCAAGTTTACAGTTTCAACCGAATCAAGATAT 3234
QY 3223 GTGTTACGAGTTTACTGCGAGAAAGAGGGGTAGGAAATGATATGTAAGTATCCGTGAT 3282
Db 3235 GTGTTACGAGTTTACTGCGAGAAAGAGGGGTAGGAAATGATATGTAAGTATCCGTGAT 3294
QY 3283 GGTGGAATTCACACAGAGAGCGTTACTTTTGTGTCAGAGGATATGATACAAATGGAATG 3342
Db 3295 GGTGGAATTCACACAGAGAGCGTTACTTTTGTGTCAGAGGATATGATACAAATGGAATG 3354
QY 3343 TATAATACGGAAGTGTCCAAATCAAAATGGAATATACCAAAATATGCGTATATACACAA 3402
Db 3355 TATAATACGGAAGTGTCCAAATCAAAATGGAATATACCAAAATATGCGTATATACACAA 3414
QY 3403 GCATCCAGTACAAACGGATATACCAATATATGATATATACGCAAGCATCGAATACA 3462
Db 3415 GCATCCAGTACAAACGGATATACCAATATATGATATATACGCAAGCATCGAATACA 3474
QY 3463 AACGGATATACCAAAATATGTTGATCAATGATCAAAACCGGCTATATACCAAAACAGTG 3522
Db 3475 AACGGATATACCAAAATATGTTGATCAATGATCAAAACCGGCTATATACCAAAACAGTG 3534
QY 3523 ACATTCATCCCGTATACAGATCAAAATGGAATTCAGATGAGTACAGAGGATGATTC 3582
Db 3535 ACATTCATCCCGTATACAGATCAAAATGGAATTCAGATGAGTACAGAGGATGATTC 3594
QY 3583 TATATAGAAAGTGTAGAAATGATTTAGACCTGAGGTAA 3621
Db 3595 TATATAGAAAGTGTAGAAATGATTTGATAGACCTGAGGTAA 3633
```

## RESULT 4

US-10-032-717-28  
; Sequence 28, Application US/10032717  
; Patent No. US20020151709A1

GENERAL INFORMATION:  
; APPLICANT: Andre R. Abad  
; APPLICANT: Nicholas B. Duck  
; APPLICANT: Xiang Peng  
; APPLICANT: Ronald D. Flannagan  
; APPLICANT: Theodore W. Kahn  
; APPLICANT: Lynn S. Sline  
; TITLE OF INVENTION: Genes Encoding No. US20020151709A1el Proteins With  
; FILE REFERENCE: 35718/237005  
; CURRENT APPLICATION NUMBER: US/10/032.717  
; PRIORITY FILING DATE: 2001-10-23  
; PRIOR APPLICATION NUMBER: 60/242,838  
; NUMBER OF SEQ ID NOS: 48  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 28  
; LENGTH: 6613  
; TYPE: DNA  
; ORGANISM: Bacillus thuringiensis  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (0) - (0)  
; OTHER INFORMATION: Genomic Cyl1218-2  
US-10-032-717-28

Query Match 87.0%; Score 3151.8; DB 12; Length 6613;  
Best Local Similarity 92.1%; Pred. No. 0;  
Matches 3353; Conservative 0; Mismatches 262; Indels 24; Gaps 2;  
QY 1 ATGAGTCCAAATTAATCAAAATGAAATATGAAATATAGATGCGACACCTCTCTCTCTGTA 60  
Db 1254 ATGAGTCCAAATTAATCAAAATGAAATATGAAATATAGATGCGACACCTCTCTCTCTGTA 1313  
QY 61 TCCAAATGATTTCAACAGATACCCCTTTTGGGAATGAGCAACAAATGCGCTACAAATATG 120  
Db 1314 TCCAAATGATTTCAACAGATACCCCTTTTGGGAATGAGCAACAAATGCGCTACAAATATG 1373  
QY 121 GATTATAAAGATTATTTAAATAATGCTGCGGAAATGCTAGTCAATACCCCTGCTCACCT 180  
Db 1374 GATTATAAAGATTATTTAAATAATGCTGCGGAAATGCTAGTCAATACCCCTGCTCACCT 1433  
QY 181 GAAGTACTTTGTTAGCGGCAAGATGCGAGCTTAGCCCAATGATATATAGTAGTAATTA 240  
Db 1434 GAAGTACTTTGTTAGCGGCAAGATGCGAGCTTAGCCCAATGATATATAGTAGTAATTA 1493  
QY 241 CTATCAAGTTTATGAGGCTCCCATTTTGTGGGCGGATAGTCTTTATATCTCAACTTAT 300  
Db 1494 CTATCAAGTTTATGAGGCTCCCATTTTGTGGGCGGATAGTCTTTATATCTCAACTTAT 1553  
QY 301 GATATCTGTGGCCTTCAGGGGAAAGATGCAATGCGAAATTTTATGGAACAGTAGAA 360  
Db 1554 GATATCTGTGGCCTTCAGGGGAAAGATGCAATGCGAAATTTTATGGAACAGTAGAA 1613  
QY 361 GAATCAATTAATCAAAATATAGCAAGATATGCAAGGAATAAAGCGCTTTCGGAATTAGAA 420  
Db 1614 GAATCAATTAATCAAAATATAGCAAGATATGCAAGGAATAAAGCGCTTTCGGAATTAGAA 1673  
QY 421 GGAATAGGTAAATTAATCAATATATCTAAGCTTCAAGGATGCGGAGGAAATCCA 480  
Db 1674 GGAATAGGTAAATTAATCAATATATCTAAGCTTCAAGGATGCGGAGGAAATCCA 1733  
QY 481 AATGTTCAAGAGCTTTACAGAGATGTCGAAATTCGAATTCGAATTCCTGGATAGTTATTT 540  
Db 1734 AATGTTCAAGAGCTTTACAGAGATGTCGAAATTCGAATTCGAATTCCTGGATAGTTATTT 1793  
QY 541 ACGCAATATATGCCATCTTTTAGAGTACAAATTTTGAAGTACCATTTCTTACGTATAT 600  
Db 1794 ACGCAATATATGCCATCTTTTAGAGTACAAATTTTGAAGTACCATTTCTTACGTATAT 1853  
QY 601 GCATGCGGAGCGCAACCTTTCATTTATTAAGGAACCGCTCAATTTTGGAGAGAA 660  
Db 1854 ACACAGGCGGAGCGCAACCTTTCATTTATTAAGGAACCGCTCAATTTTGGAGAGAA 1913